Market Analysis and Insights: Infectious Disease Drug Market
Infectious Disease Drug Market By Source Type (Bacterial Diseases, Virusal Diseases, Fungal Disease and Parasitic Disease), By Disease Type (Jaundice, Leprosy, Listeria, Lyme disease, Malaria, Measles, Molluscum contagiosum, Molluscum contagiosum, Norovirus, Pyelonephritis, Rabies, Severe acute respiratory syndrome, Sepsis, Tetanus, West Nile, Zika, Ebola disease and Others) By Treatment Type (Medication, Dietary supplements and surgery), By Mode of Action Type (Antibacterial drugs, Antiviral drugs, Antifungal drugs, Antiparasitic drugs ), By Drug Type (Tafenoquine, Omadacycline, Tecovirimat, Eravacycline, Delafloxacin, Plazomicin, Benznidazole, Secnidazole, Daclatasvir, Dalbavancin and Others), By Route of Administration (Oral, Topical and intravenous), By End- users (Hospitals, Homecare, Specialty Clinics, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends & Forecast to 2026
Download Free PDF Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=glo...
Global infectious disease drugs market is rise gradually to an estimated value of USD 72.49 Billion by 2026 registering a CAGR of 5.5% in the forecast period of 2019-2026 with the annual sales of USD 47.24 billion in the year 2018. This significant rise in market value can increases research development initiatives to launching novel therapies.
Market Definition: Global Infectious Disease Drug Market
Infectious disease is defined as pathogenic microorganism disease caused by infectious agent such as bacteria, viruses, fungi and parasites. It can spread from one person to another healthy individual. People who have likely to developed weakened immune system, this could be due to drugs, age, or other diseases and people who they have not been vaccinated before are prone to the infections.
According to the article published in our World in Data 2016, the global burden of infectious disease was responsible for 10.0 % of causes of death in the world. It is identified that over 229.96 million patients affected with diarrhea and infectious disease. Increases of cases of prevalence rate, Advances in nutrition, antibiotics and immunization. Accelerate demanding of novel therapies and newer developments in diagnostic devices and Government initiatives in sanitization and regulations for food safety are the drivers for market growth.
Market Drivers
• Increases of cases of prevalence rate of infectious diseases worldwide
• Advances in nutrition, antibiotics and immunization
• Accelerate demanding of novel therapies and newer development in diagnostic devices
• Rising awareness about treatment and technological advancement is driving the growth of market
• Prevalence of indoor as well as outdoor infections
• Government initiatives programs in sanitization and regulations for food safety
Inquire before Buy @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbm...
Market Restraints
• Effective treatment is either unavailable or unaffordable.
• Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market.
• Lack of awareness among the patient and physician about asthma disease treatment.
Segmentation: Global Infectious Disease Drug Market
By Source Type
• Bacterial Diseases
• Viruses Diseases
• Fungus Disease
• Parasites Disease
By Disease Type
• Jaundice
• Leprosy
• Listeria
• Lyme disease
• Malaria
• Measles
• Molluscum contagiosum
• Norovirus
• Pyelonephritis
• Rabies
• Severe acute respiratory syndrome
• Sepsis
• Tetanus
• West Nile
• Zika
• Ebola disease
• Others
By Treatment
• Medication
• Dietary supplements
• Surgery
By Route of administration
• Oral
• Topical
• Injectable
By End users
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Geography
• North America
o U.S.
o Canada
o Mexico
• South America
o Brazil
o Argentina
o Rest of South America
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Turkey
o Belgium
o Netherlands
o Switzerland
o Rest of Europe
• Asia-Pacific
o Japan
o China
o South Korea
o India
o Australia
o Singapore
o Thailand
o Malaysia
o Indonesia
o Philippines
o Rest of Asia Pacific
• Middle East & Africa
o South Africa
o Egypt
o Saudi Arabia
o United Arab Emirates
o Israel
o Rest of Middle East & Africa
Get Detailed Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-infectiou...
Key Developments in the Market:
On 01 May 2019, Sanofi S.A received FDA approval for Dengvaxia (Dengue Tetravalent Vaccine, Live) for the prophylaxes of dengue disease caused by dengue virus serotypes (1, 2, 3 and 4) in patient upto 9 years old. Dengvaxia also received European Commission approval for treatment of Dengue fever in European endemic areas.
On 8 April 2019, ViiV Healthcare group of companies received FDA approval for Dovato (dolutegravir and lamivudine), a fixed dose combination for the treatment of HIV-infected adults patients who have never treated by any antiretroviral drugs.
0n 13 Feb 2019, Novartis AG received the FDA approval for Egaten (triclabendazole) for the treatment of liver flukes specifically caused by fascioliasis and paragonimiasis. WHO recognized Egaten in an essential medicines lists.
Competitive Analysis:
Global Infectious Disease Drug Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Infectious Disease market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players:
Few of the major competitors currently working in the Infectious Disease market are F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (US), GlaxoSmithKline Plc (UK), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Pfizer Inc. (US), AbbVie Inc. (US), Vertex Pharmaceuticals Incorporated (US), ViiV Healthcare group of companies (UK), Sanofi S.A (France), Eli Lilly and Company (US) , Novartis AG (Switzerland), Mitsubishi Tanabe Pharma Corporation (Japan) and few among others.
Browse more related report to know about market analysis
• Asia-Pacific Anti-Nuclear Antibody Test Market
• Asia-Pacific Rx Dermatology Topical Drug Delivery Market
• Europe Anticoagulation Therapy Market
• Europe Dry Eye Syndrome Treatment Market
• Ameloblastic Carcinoma Market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact: Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]